CARLSBAD, Calif.--(BUSINESS WIRE)--April 11, 2006--Invitrogen Corporation (Nasdaq:IVGN - News), a provider of essential life science technologies for disease research and drug discovery, today announced a collaborative agreement with Signalomics (Steinfurt, Germany) to develop nanocrystal reagents with the ability to enhance the identification of tumors in in vivo patient tissue by detecting the presence of a single cancerous cell -- improving the ability to excise the tumor more rapidly and completely. The initial goal of the collaboration is to develop an imaging agent that can be used to identify colon carcinomas requiring surgical intervention.
